To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.

To determine if MSCs elicit an immune response after repeated infusions.

To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy.

5

All

up to 19 Years (Child, Adult)

NCT01061099

2008-4-5947

STOD3

February 2010

March 2013

February 2014

February 2, 2010

April 24, 2015

The Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania, United States

† Study has passed its completion date and status has not been verified in more than two years.